SCHEMBL5801150

SCHEMBL5801150

CCc1ccc(C(=O)n2c(C)c(CC(=O)O)c3cc(OC)ccc32)cc1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 9/20 0.87
AKR1C2 P52895 8/20 0.87
AKR1C4 P17516 2/20 0.84
AKR1C1 Q04828 2/20 0.84
HIF1A Q16665 3/20 0.81
LMNA P02545 2/20 0.81
CYP1A2 P05177 2/20 0.81
CYP2D6 P10635 2/20 0.81
CYP2C9 P11712 2/20 0.81
NPSR1 Q6W5P4 2/20 0.81
TSHR P16473 1/20 0.81
NFKB1 P19838 1/20 0.81
PTGS2 P35354 4/20 0.80
ABCB1 P08183 2/20 0.80
PTGS1 P23219 2/20 0.80
GLO1 Q04760 2/20 0.80
KDM4E B2RXH2 1/20 0.80
MEN1 O00255 1/20 0.80
PTGES O14684 1/20 0.80
ABCC3 O15438 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8645594 0.93 AKR1C3 (1.00) AKR1C3AKR1C2AKR1C4AKR1C1HIF1A
SCHEMBL14351102 0.91 AKR1C3 (0.83) AKR1C3AKR1C2AKR1C4AKR1C1HIF1A
SCHEMBL14886867 0.91 AKR1C3 (1.00) AKR1C3AKR1C2AKR1C4AKR1C1HIF1A
SCHEMBL2600801 0.91 AKR1C3 (1.00) AKR1C3AKR1C2AKR1C4AKR1C1HIF1A
SCHEMBL8647232 0.91 AKR1C3 (0.78) AKR1C3AKR1C2AKR1C4AKR1C1HIF1A
SCHEMBL12747878 0.90 AKR1C3 (0.89) AKR1C3AKR1C2AKR1C4AKR1C1HIF1A
SCHEMBL1082631 0.90 HIF1A (1.00) AKR1C3AKR1C2AKR1C4AKR1C1HIF1A
Indomethacin SCHEMBL25313463 0.89 PTGS2 (0.92) AKR1C3AKR1C2AKR1C4AKR1C1HIF1A
SCHEMBL5646082 0.89 AKR1C3 (0.76) AKR1C3AKR1C2AKR1C4AKR1C1HIF1A
SCHEMBL5645861 0.89 AKR1C3 (0.76) AKR1C3AKR1C2AKR1C4AKR1C1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3078374-B1 INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER UNIV VANDERBILT (US) 2019-06-19 EP disclosed
WO-2006050120-A2 SYNTHESIS OF COX-2 AND FAAH INHIBITORS MICROBIA, INC. (US) 2006-05-11 WO disclosed
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 AKR1C3 577/4885AKR1C2 563/4885AKR1C4 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.